Free Trial

Extendicare (TSE:EXE) Share Price Passes Above 200 Day Moving Average - Time to Sell?

Extendicare logo with Medical background
Remove Ads

Extendicare Inc. (TSE:EXE - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$10.32 and traded as high as C$13.17. Extendicare shares last traded at C$13.09, with a volume of 111,826 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Cormark upgraded shares of Extendicare to a "moderate buy" rating in a research report on Wednesday, February 19th. BMO Capital Markets raised their price objective on shares of Extendicare from C$11.00 to C$13.50 in a report on Monday, March 3rd. Finally, TD Securities boosted their target price on shares of Extendicare from C$10.50 to C$13.00 and gave the company a "hold" rating in a report on Monday, March 3rd.

View Our Latest Report on EXE

Extendicare Stock Performance

The business's fifty day moving average price is C$11.75 and its 200-day moving average price is C$10.45. The company has a debt-to-equity ratio of 283.02, a current ratio of 0.62 and a quick ratio of 0.98. The stock has a market capitalization of C$1.09 billion, a PE ratio of 16.60 and a beta of 1.26.

Extendicare Announces Dividend

The firm also recently disclosed a monthly dividend, which was paid on Monday, March 17th. Investors of record on Monday, March 17th were paid a dividend of $0.04 per share. This represents a $0.48 annualized dividend and a yield of 3.69%. The ex-dividend date was Friday, February 28th. Extendicare's dividend payout ratio is 61.20%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Further Reading

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads